Role of serum neutralizing antibody in reinfection of respiratory syncytial virus

Pediatrics International

Volumn 46, Issue 2, 2004, Pages 126-129

  Kawasaki, Yukihiko ^a,b,c   Hosoya, Mitsuaki ^b   Katayose, Masahiko ^a   Suzuki, Hitoshi ^b  

^a Soma General Hospital   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c NONE   (Japan)

Author keywords

Neutralization test antibody; Reinfection; Respiratory syncytial virus

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COUGHING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; NOSE SECRETION; OXYGENATION; PRIMARY INFECTION; PRIORITY JOURNAL; REINFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RHINORRHEA; SERODIAGNOSIS; VIRUS INFECTION; WHEEZING; WINTER;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; NEUTRALIZATION TESTS; RECURRENCE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEVERITY OF ILLNESS INDEX;

EID: 1942422171     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200x.2004.01860.x     Document Type: Article

References (10)

1. Kim HW, Arrobio JO, Brandt CD et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C.I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am. J. Epidemiol. 1973; 98: 216-25.
2. Henderson FW, Collier AM, Clyde WA, Denny FW. Respiratory syncytial virus infections, reinfection and immunity. N. Engl. J. Med. 1979; 300: 530-4.
3. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child 1986; 140: 543-6.
4. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82: 199-230.
5. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. Respiratory syncytial viral infection in infants with congenital heart disease. N. Engl. J. Med. 1982; 307: 397-400.
6. Hall CB, Powell KR, MacDonald NE et al. Respiratory syncytial viral infection in infants with compromised immune function. N. Engl. J. Med. 1986; 315: 77-81.
7. Kaneko M, Watanabe J, Ueno E, Hida M, Sone T. Risk factors for severe respiratory syncitial virus-associated lower respiratory tract infection in children. Pediatr. Int. 2001; 43: 489-92.
8. Groothuis JR, Simoes EAF, Hemming VG et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 1993; 329: 1524-30.
9. Groothuis JRMD, Simoes EAFMD, Hemming VGMD and the Respiratory Syncytial Virus Immune Globulin Study Group. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 1995; 95: 463-7.
10. Sandritter T. Palivizumab for respiratory syncytial virus prophylaxis. J. Pediatr. Health Care 1999; 13: 191-5.